Related Experiment Video
Updated: May 30, 2026

Shotgun Lipidomics of Rodent Tissues
Published on: November 18, 2022
Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the
Ann B Nguyen1, Anand Rohatgi, Christine K Garcia
1Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9047, USA.
Objective:
Pulmonary surfactant protein B (SP-B), an alveolar protein normally detectable at only very low concentrations in blood, circulates at higher levels among smokers and those with alveolar injury and inflammation. We hypothesized that SP-B may serve as a marker of the vascular effects of smoking and would thus be associated with subclinical measures of atherosclerosis.
Methods And Results:
Plasma levels of SP-B were measured in 3294 subjects, ages 30 to 65, enrolled in the Dallas Heart Study, a probability-based population sample of Dallas County adults. Coronary artery calcium (CAC) was measured by computed tomography and abdominal aortic plaque (AP) by magnetic resonance imaging. The cohort comprised 29% current and 17% former smokers. The overall prevalence of CAC was 22%, and that of AP was 39%. Median SP-B levels were 5-fold higher among current versus never smokers (P<0.0001) and were significantly correlated with estimated pack-years smoked (Spearman ρ=0.35, P<0.0001). Increasing levels of SP-B also associated with other traditional cardiac risk factors and higher levels of inflammatory biomarkers. In univariable analyses, increasing SP-B quartiles associated with higher prevalence of both CAC and AP (P(trend)<0.0001 for each). In multivariable analyses adjusting for traditional cardiovascular risk factors, SP-B remained associated with AP (OR 1.87 for the 4th versus 1st quartiles, 95% confidence interval 1.39 to 2.51; P<0.0001) but not CAC. An interaction was observed between SP-B, smoking status, and AP (P(interaction)=0.01), such that SP-B associated with AP in current smokers (adjusted OR 2.15 for the 4th versus 1st quartile, 95% confidence interval 1.26 to 3.67; P=0.005) but not in former or never smokers.
Conclusions:
Circulating levels of SP-B increase with greater smoking burden and independently associate with abdominal AP among current smokers. Our findings support further investigation of the role of SP-B as a marker of the vascular effects of smoking.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Coronary Artery Disease I: Introduction
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Coronary Artery Disease II: Pathophysiology

